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Abstract
Background: AIDS develops typically after 7–11 years of untreated HIV-1 infection, with extremes of very rapid disease
progression (,2 years) and long-term non-progression (.15 years). To reveal additional host genetic factors that may
impact on the clinical course of HIV-1 infection, we designed a genome-wide association study (GWAS) in 404 participants
of the Amsterdam Cohort Studies on HIV-1 infection and AIDS.
Methods: The association of SNP genotypes with the clinical course of HIV-1 infection was tested in Cox regression survival
analyses using AIDS-diagnosis and AIDS-related death as endpoints.
Results: Multiple, not previously identified SNPs, were identified to be strongly associated with disease progression after
HIV-1 infection, albeit not genome-wide significant. However, three independent SNPs in the top ten associations between
SNP genotypes and time between seroconversion and AIDS-diagnosis, and one from the top ten associations between SNP
genotypes and time between seroconversion and AIDS-related death, had P-values smaller than 0.05 in the French
Genomics of Resistance to Immunodeficiency Virus cohort on disease progression.
Conclusions: Our study emphasizes that the use of different phenotypes in GWAS may be useful to unravel the full
spectrum of host genetic factors that may be associated with the clinical course of HIV-1 infection.
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Introduction
The clinical course of HIV-1 infection can be highly variable
between individuals. The period of asymptomatic disease after
HIV-1 infection in the absence of antiviral therapy is typically 7–11
years [1,2], with extremes of disease progression within 2 years, or
virtually no disease progression for more than 15 years [3]. The
genetic make-up of an individual has been shown to play a role in
the susceptibility to HIV-1 infection and/or the rate of disease
progression. Some of the observed variation could be attributed to
human leukocyte antigen (HLA) types. In the Caucasian popula-
tion, HLA-B5701 and HLA-B27 are most strongly associated with
prolonged survival, whereas a variant of HLA-B35 is linked to an
accelerated progression to AIDS [4–7]. Another well known
example is the 32 base pair deletion in the gene coding for the
chemokine receptor CCR5 that serves as a coreceptor for HIV-1.
This polymorphism has been associated with reduced susceptibility
to infection [8,9] and a slower rate of disease progression [10–12].
However, all host genetic factors identified to date can explain the
clinical course of HIV-1 infection in only a minority of individuals
[13,14].
In the last couple of years several genome-wide association
studies (GWAS) have been published to reveal additional host
genetic factors that are associated with HIV-1 control. Fellay et al
published two single nucleotide polymorphisms (SNP) on chro-
mosome 6, one located in HCP5 (rs2395029) and in high linkage
disequilibrium (LD) with HLA-B57, and one at position -35 in the
HLA-C gene region (rs9264942), to be associated with a lower
viral load set-point [14,15], which could be confirmed by us and
others [16,17]. Other GWAS confirmed the important role of the
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infection, and found potentially interesting additional associations
which need confirmation in other cohorts [18–23].
Although HIV-1 viral load is established as a good predictor for
AIDS disease progression [24,25], several studies have shown that
it is not the sole determinant for variation in disease progression
and CD4
+ T-cell depletion [26–28]. To reveal additional host
genetic factors that are associated with the clinical course of HIV-1
infection, we designed a GWAS in the Amsterdam Cohort Studies
(ACS) on HIV-1 infection and AIDS and examined the association
between SNPs and the time between seroconversion and AIDS-
diagnosis or AIDS-related death.
Results
Time from seroconversion to AIDS-diagnosis or AIDS-related
death was normally distributed in the ACS (Figure 1). To find host
genetic markers that associate with disease progression after HIV-
1 infection, we genotyped 455 samples with Illumina’s Infinium
HumanHap300 BeadChip which assays 317,503 SNPs [29]. After
quality control (see Methods) and population stratification,
association analysis was performed for 309,494 SNPs and HIV-1
disease course in 404 HIV-1 infected MSM and DU from the ACS
using Cox regression survival analyses with AIDS according to the
CDC 1993 definition [30] or AIDS-related death, as endpoints.
The calculated l values of 1.0231 and 1.0197 for the P-values of
SNP associations with either AIDS-free survival or time to AIDS-
related death, respectively, indicate that the remaining popula-
tion stratification effect, after correction by using the two first
eigenvectors as covariates, is minimal.
The top 10 associations between SNP genotypes and time to
AIDS-diagnosis, had P-values smaller than 5.25610
25, with
P=3.50610
26 for the strongest statistical association (SNP
rs1523635; Table 1). The top 10 associations between SNP
genotypes and time to AIDS-related death had P-values smaller
than 4.43610
25, with P=8.32610
26 for the strongest statistical
association (SNP rs7374396; Table 2). None of the associations
between SNP genotypes and time to AIDS or AIDS-related death
were genome-wide significant. However, the minor alleles of SNPs
that ranked in the top 10 for association with time to AIDS or
AIDS-related death were also associated with survival to other
endpoints (Tables 1 and 2). None of the SNP genotypes identified
to be associated with AIDS-diagnosis were associated with survival
time after AIDS-diagnosis, indicating that their potential effect is
at an earlier stage in the course of infection (Table 1).
The potential associations of the top 10 SNPs for both end
points were then in a 2
nd phase analysis studied for confirmation in
an independent and well-defined cohort of HIV-1-infected
individuals. The Genomics of Resistance to Immunodeficiency
Virus cohort (GRIV) is a French case-control study in which either
rapid progressors or non-progressors were compared with HIV-1-
negative controls [18,20].
Three independent signals (four SNPs) that were associated with
time to AIDS in our cohort had a P-value below 0.05 and a similar
polarity in the GRIV cohort (Table 1). SNP rs1523635, which had
the strongest association with a more rapid progression to AIDS in
our cohort was also associated with rapid progression in the GRIV
(P=2.42610
22). SNPs rs6845554 and rs6827754, which are in
complete LD (r
2=1) were both associated with rapid progression
in the GRIV cohort as well (P=2.75610
22). Finally, SNP
rs6018199 was associated with non-progression in the ACS cohort
as well as in the GRIV cohort (P=4.22610
23).
Of the top 10 associations between SNP genotypes and time
between seroconversion and AIDS-related death, the minor allele
of SNP rs1434975 was associated with rapid progression in the
ACS and in the GRIV cohort on extremes in disease progression
(P=3.37610
22; Table 2).
Discussion
We identified novel genetic loci that may be associated with the
clinical course of HIV-1 infection in the ACS. None of the
associations between SNPs and time to AIDS or time to AIDS-
related death that ranked in the top 10, were genome-wide
significant. Interestingly, the majority of the SNPs involved were
also associated with other phenotypes that are related to HIV-1
infection, such as set-point viral load, although one could argue
that those are not independent phenotypes. Furthermore, three
independent signals that ranked in the top 10 for associations with
time to AIDS, and one SNP from the top 10 associations with time
to AIDS-related death, were also associated with disease course in
the GRIV cohort of HIV-1 infected individuals, with the same
effect of the minor allele on disease progression. This independent
confirmation is evidence for an actual association between the
identified gene regions and HIV-1 disease course, and not a
statistical artifact.
The four gene regions that were found to be associated with
disease progression in both ACS and GRIV are distributed around
the genome. SNP rs1523635 is located 90 kb downstream of
Anterior Gradient Homolog 3 (AGR3), alias Breast Cancer
Figure 1. Distribution of the clinical course of HIV-1 infection in the ACS. Time from seroconversion to (A) AIDS-diagnosis or (B) AIDS-related
death.
doi:10.1371/journal.pone.0022208.g001
GWAS on AIDS Disease Progression
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to interact with LY6/PLAUR Domain Containing 3 (LYPD3),
and the LY6 family has been associated with HIV-1 disease
progression although the mechanism is unknown [31]. SNPs
rs6845554 and rs6827754, which are in high LD, are both located
intronic of Solute Carrier Family 2, Member 9 Protein (SLC2A9).
A potential effect of this gene on the clinical course of HIV-1
infection has not been reported. SNP rs6018199 is located in an
intron of the Proto-Oncogene Tyrosine-Protein Kinase (SRC).
The HIV-1 Nef gene was found to selectively activate certain
members of the SRC kinase family, including SRC itself, which
may contribute to HIV-1-associated nephropathy which is the
most common cause of chronic renal failure in HIV-1-infected
individuals [32].
The SNP that was found to be associated with time to AIDS-
related death in the ACS and associated with disease progression
in the GRIV is SNP rs1434975. This SNP is located 25 kb
downstream of the gene Family with Sequence Similarity 84,
Member A (FAM84A). The function of the gene is largely
unknown and interaction with HIV-1 has not been reported.
None of the top 10 SNPs identified in our present study map to
gene regions that were identified in previous GWAS on HIV-1
control that mainly identified associations between HIV-1 control
and SNPs on chromosome 6 [14,15,18–20]. In a previous study,
we were able to confirm SNP rs2395029 in the HCP5 gene region,
in complete linkage with HLA-B57, and SNP rs9264942 upstream
of the HLA-C gene, that were identified by Fellay et al [15] to be
associated with viral load set-point and/or CD4
+ T-cell depletion.
In our GWAS, however, these associations did not have genome-
wide significant P-values [16]. Moreover, HLA-B57 and HLA-B27
were also only associated with time from seroconversion until
AIDS-diagnosis but not with time between AIDS-diagnosis and
Table 1. P-values for different endpoints in survival analysis and viral load set-point of top 10 SNPs associated in GWA study with
time to AIDS-diagnosis.
ACS GRIV 2
nd phase
SNP CHR Coordinate Gene Position MAF AIDS CD4,400 Death
AIDS to
Death
viral load
set-point
NP vs
Ctrl
RP vs
CTRL
rs1523635 7 16982220 AGR3 90kb 39 0.30 3.50E-06 ns 6.91E-05 ns 6.94E-03 2.42E-02 ns
rs4722020 7 21391068 SP4 40kb 59 0.20 2.40E-05 8.29E-03 2.07E-03 ns ns ns ns
rs6845554 4 9622271 SLC2A9 intron 0.40 2.90E-05 ns 2.36E-04 ns ns ns 2.75E-02
rs6827754 4 9627251 SLC2A9 intron 0.40 2.97E-05 ns 2.37E-04 ns ns ns 2.75E-02
rs2460000 1 2146222 SKI 5kb 59 0.34 3.14E-05 9.72E-04 1.36E-04 ns 1.51E-04 ns ns
rs4973374 2 231593659 SPATA3 30kb 59 0.45 3.17E-05 1.80E-04 1.15E-05 ns 6.02E-03 ns ns
rs3790623 1 37942165 CDCA8 intron 0.24 3.42E-05 5.12E-03 6.54E-04 ns 1.58E-02 ns ns
rs1979738 15 31738020 RYR3 intron 0.31 3.74E-05 1.76E-02 1.01E-03 ns ns ns ns
rs6018199 20 35443071 SRC intron 0.14 5.11E-05 1.65E-03 3.07E-03 ns ns ns 4.22E-03
rs3753264 1 119711037 HAO2 5kb 59 0.31 5.25E-05 2.22E-02 1.45E-03 ns ns ns ns
ACS; Amsterdam Cohort Studies, GRIV; Genomics of Resistance to Immunodeficiency Virus cohort, CHR; chromosome, MAF; minor allele frequency, ns; not significant
(P.5.00610
22).
doi:10.1371/journal.pone.0022208.t001
Table 2. P-values for different endpoints in survival analysis and viral load set-point of top 10 SNPs associated in GWA study with
time to AIDS-related death.
ACS GRIV 2
nd phase
SNP CHR Coordinate Gene Position MAF AIDS CD4,400 Death
AIDS to
Death
viral load
set-point
NP vs
Ctrl
RP vs
CTRL
rs7374396 3 33645348 CLASP2 intron 0.27 8.32E-06 6.59E-05 4.62E-03 5.76E-03 4.45E-04 ns ns
rs4485771 4 167112983 TLL1 intron 0.28 1.06E-05 2.59E-02 1.99E-04 ns ns ns ns
rs4973374 2 231593659 SPATA3 30kb 59 0.45 1.15E-05 1.80E-04 3.17E-05 ns 6.02E-03 ns ns
rs2189915 7 80839680 Intergenic 0.32 1.61E-05 ns 4.40E-03 8.65E-04 9.89E-03 ns ns
rs1434975 2 14722893 FAM84A:NSE1 25kb 39 0.37 2.46E-05 ns 1.36E-02 ns ns ns 3.37E-02
rs3743833 16 10035456 GRIN2A intron 0.13 3.71E-05 1.56E-03 5.56E-05 ns 6.41E-04 ns ns
rs9379174 6 8167773 Intergenic 0.21 3.98E-05 ns 1.22E-02 ns 4.20E-02 ns ns
rs1570023 20 60419644 C20orf151 intron 0.18 4.07E-05 2.44E-02 2.18E-02 4.56E-02 1.09E-02 ns ns
rs541821 11 94801223 Intergenic 0.32 4.24E-05 2.98E-03 1.80E-02 ns 7.92E-03 ns ns
rs2256688 10 44584427 Intergenic 0.30 4.43E-05 4.59E-02 2.96E-04 ns ns ns ns
ACS; Amsterdam Cohort Studies, GRIV; Genomics of Resistance to Immunodeficiency Virus cohort, CHR; chromosome, MAF; minor allele frequency, ns; not significant
(P.5.00610
22).
doi:10.1371/journal.pone.0022208.t002
GWAS on AIDS Disease Progression
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transmission route, study design (case-control versus survival
analysis), phenotype used for association, or other yet unknown
factors may explain the variable outcome of different studies.
Indeed, two studies that also used survival time as a phenotype
identified signals outside the chromosome 6 HLA-gene region as
well [21,23]. This illustrates that different end-points should be
used to unravel the full spectrum of host genetic factors that may
be associated with the clinical course of the infection.
The lack of confirmation of SNP associations with phenotypes
related to HIV-1 disease may point to false-positive associations.
However, it cannot be excluded that lack of confirmation relates to
the calendar time of seroconversion of the cohort participants in
combination with the adaptation of HIV-1 to its host environment
Indeed, certain associations between host genetic background and
the clinical course of infection or viral load set-point have
disappeared over time at a population level [33,34] (van Manen et
al, submitted for publication).
GWAS may reveal genes that can be considered new targets for
drug development. In addition, SNPs strongly associated with
HIV-1 disease progression, like the SNPs identified in this study,
may be applied in routine diagnostics to predict disease course, or
to more accurately estimate if antiviral therapy should be initiated.
Indeed, screening for polymorphisms in the human genome that
influence the course of infection may ultimately allow for a better
fine-tuning of patient management.
Materials and Methods
Study population
We studied HIV-1 infected men who have sex with men (MSM)
and drug users (DU) who participate in the ACS on HIV infection
and AIDS. The HIV-infected MSM were enrolled in the cohort
between October 1984 and March 1986 [35]. In the first serum
sample taken at entry in the cohort, 239 men tested positive for
HIV antibodies (recombinant HIV-1/-2 enzyme immunoassay
(Abbott, Chicago, Illinois) with an HIV-1 Western blot IgG assay
(version 1.2, Diagnostic Biotechnology Ltd., Singapore) for
confirmation; five of these men refused to participate further. Of
the HIV-1 negative men, 131 subsequently seroconverted during
active follow-up (until May 1996). For seroprevalent individuals,
an imputed seroconversion date (on average 18 months before
entry into the ACS) was used [36]. Seroprevalent individuals and
prospective seroconverters were studied as one group [11,16].
Most seropositive men (n=243 [67%]) did not receive any early
treatment, 70 (19%) received zidovudine monotherapy, 10 (3%)
received didanosine monotherapy, and 42 (11%) received other
ineffective antiretroviral therapy before AIDS-diagnosis. The
mean age of participants at the time of (imputed) seroconversion
was 34.5 years (range 19.5–57.7 years). A DNA sample was
available from 335 of these 365 cohort participants for genotyping
analysis (205 seroprevalent cases and 130 seroconverters). This
cohort of MSM has been used for confirmation of host genetic
factors and disease course [37–40].
The participants of the ACS on HIV and AIDS among DU
started enrolment in 1985 [41]. Asymptomatic men and women
who were living in the Amsterdam area and who reported
intravenous drug use in the preceding 6 months were enrolled in a
prospective study on the prevalence and incidence of HIV-1
infection and risk factors for AIDS. We included 83 individuals
who seroconverted for HIV antibodies during active follow-up. At
entry in the cohort study 37 individuals were positive for HIV
antibodies but had a negative test result before entry (i.e.,
retrospective seroconverters). For all 120 HIV-1 infected DU (76
men and 44 women) used for our present analysis, the imputed
seroconversion date was calculated and used for further analysis
[42]. Mean survival time was similar for male and female
participants of the DU cohort and for the DU versus MSM
cohorts. Most seropositive DU (n=69 [58%]) did not receive any
early treatment, 28 (23%) received zidovudine monotherapy, and
23 (19%) received other ineffective antiretroviral therapy before
AIDS-diagnosis. The mean age of DU participants at the time of
(imputed) seroconversion was 31.5 years (range 19.1–55.9 years).
A DNA sample was available from all 120 DU participants, hence
all were included in further analyses.
The ACS has been conducted in accordance with the ethical
principles set out in the declaration of Helsinki and all participants
provided written informed consent. The study was approved by
the Academic Medical Center institutional Medical Ethics
Committee of the University of Amsterdam.
Genome-wide association scan genotyping
Genotyping was performed according to the Infinium II
protocol from Illumina (Illumina, San Diego, USA) [29]. Samples
were only included if a minimum 95% call rate was observed for
the sample in BeadStudio 3.1 data analysis software (Illumina Inc,
San Diego, USA). Three samples that had a call rate below 95%
were repeated using a new DNA aliquot and analyzed successfully.
GWA quality control and linkage disequilibrium
SNPs were excluded from analysis for the following reasons
(applied in order): call rate ,95% (n=1910), allele frequency
,1% in (n=280) and deviation from Hardy Weinberg equilib-
rium (P,0.0001, n=5819). Subsequent analyses were performed
on a dataset of 309,494 SNPs.
LD was characterized using WGA Viewer [43]. WGA Viewer
was also used for creation of genome-wide overview plots, Q-Q
plots, and calculation of the genomic inflation factor l.
Identification of population stratification
Eigenstrat, implemented in Eigensoft, was used to identify
outliers in the population who were subsequently removed from
the analysis. The first two eigenvectors were used as covariates to
correct for any remaining population structure. As a result, genetic
data from 404 individuals (304 MSM and 100 DU) were used for
further analysis.
Phenotype
AIDS according to the Centers for Disease Control (CDC) 1993
definition [30] was used as an endpoint in survival analysis. The
other endpoint used in survival analysis was AIDS-related death,
defined as death with AIDS-related malignancy, death with AIDS-
opportunistic infections, or death with AIDS-related cause not
specified by the treating physician.
Virological assays
Samples collected prior to 1997 were tested using nucleic acid
sequence-based amplification (NASBA) HIV-1 RNA QT
(NASBA, bioMerieux, Boxtel, Netherlands). Samples with a viral
load below the quantification threshold of the NASBA assay (1,000
copies/ml, n=68), were re-tested in 2008 using the RealTime
HIV-1 assay (Abbott Laboratories, Abbott Park, IL) with a
threshold of 40 copies/ml. Viral load data were analyzed after
log10 transformation. Viral load set-point was defined as the
relatively steady level of HIV-1 RNA at 18–24 months after
seroconversion. Set-point viral load data were available for 385
(301 MSM and 84 DU) participants.
GWAS on AIDS Disease Progression
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Cox regression survival analysis was used to analyze genome-
wide associations for all SNP genotypes in a genotypic model and
the course of HIV-1 infection, using AIDS and AIDS-related
death as an endpoint. SNPs with less than 8 individuals
homozygous for the minor allele were excluded from the analysis
(n=74,967). Cox proportional-hazards regressions and corre-
sponding P-values were computed with ProbABEL v0.1-3 software
[44] which is based on the R library ‘survival’ developed by
Thomas Lumley (function coxfit2). The association of the SNP
with viral load set-point was tested using one-way analysis of
variance (ANOVA). All statistical analysis were performed using
GraphPad Prism 5.0 software (GraphPad Software, San Diego,
CA, USA), and the R package (http://www.r-project.org).
Confirmation study population
The Genomics of Resistance to Immunodeficiency Virus
(GRIV) cohort was established in France in 1995 to generate a
large collection of DNA for genetic studies to identify host genes
associated with either rapid progression (n=85) or non-progres-
sion (n=275) to AIDS. Further information on participants,
genotyping, quality control and statistical analysis are described in
Limou et al [18] and Le Clerc et al [20].
Acknowledgments
The Amsterdam Cohort Studies on HIV infection and AIDS are a
collaboration between the Public Health Service of Amsterdam, the
Academic Medical Center of the University of Amsterdam, the Sanquin
Blood Supply Foundation, the University Medical Center Utrecht, and the
Jan van Goyen Medical Center, and are part of the Netherlands HIV
Monitoring Foundation.
Author Contributions
Conceived and designed the experiments: HS ABvW. Performed the
experiments: DvM BDB-N JAB RvS. Analyzed the data: DvM OD NAK
SL SMB PDM. Wrote the paper: DvM ABvW HS. Careful reading of
manuscript: SJB J-FZ. Gave advice on data analysis: AHZ.
References
1. Cascade (2000) Time from HIV-1 seroconversion to AIDS and death before
widespread use of highly-active antiretroviral therapy: a collaborative re-analysis.
Collaborative Group on AIDS Incubation and HIV Survival including the
CASCADE EU Concerted Action. Concerted Action on SeroConversion to
AIDS and Death in Europe. Lancet 355: 1131–1137.
2. Veugelers PJ, Page KA, Tindall B, Schechter MT, Moss AR, et al. (1994)
Determinants of HIV disease progression among homosexual men registered in
the Tricontinental Seroconverter Study. Am J Epidemiol 140: 747–758.
3. Klein MR, Miedema F (1995) Long-term survivors of HIV-1 infection. Trends
in Microbiology 3: 386–391.
4. Navis M, Schellens I, van Baarle D, Borghans J, van Swieten P, et al. (2007)
Viral Replication Capacity as a Correlate of HLA B57/B5801-Associated
Nonprogressive HIV-1 Infection. J Immunol 179: 3133–3143.
5. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, et al.
(2000) HLA B*5701 is highly associated with restriction of virus replication in a
subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A
97: 2709–2714.
6. Gao X, Bashirova A, Iversen AK, Phair J, Goedert JJ, et al. (2005) AIDS
restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. Nat
Med 11: 1290–1292.
7. Carrington M, O’Brien SJ (2003) The influence of HLA genotype on AIDS.
Annu Rev Med 54: 535–551.
8. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, et al. (1996) Homozygous
defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed
individuals to HIV-1 infection. Cell 86: 367–377.
9. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, et al. (1996)
Genetic restriction of HIV-1 infection and progression to AIDS by a deletion
allele of the CKR5 structural gene. Science 273: 1856–1862.
10. Michael NL, Louie LG, Sheppard HW (1997) CCR5-D32 gene deletion in
HIV-1 infected patients. Lancet 350: 741–742.
11. De Roda Husman AM, Koot M, Cornelissen M, Brouwer M, Broersen SM,
et al. (1997) Association between CCR5 genotype and the clinical course of
HIV-1 infection. Ann Intern Med 127: 882–890.
12. Ioannidis JP, Rosenberg PS, Goedert JJ, Ashton LJ, Benfield TL, et al. (2001)
Effects of CCR5-Delta32, CCR2-64I, and SDF-1 39A alleles on HIV-1 disease
progression: An international meta-analysis of individual- patient data. Ann
Intern Med 135: 782–795.
13. O’Brien SJ, Nelson GW (2004) Human genes that limit AIDS. Nat Genet 36:
565–574.
14. Fellay J, Ge D, Shianna KV, Colombo S, Ledergerber B, et al. (2009) Common
genetic variation and the control of HIV-1 in humans. PLoS Genet 5: e1000791.
15. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, et al. (2007) A whole-
genome association study of major determinants for host control of HIV-1.
Science 317: 944–947.
16. van Manen D, Kootstra NA, Boeser-Nunnink B, Handulle MA, Van ’t Wout AB,
et al. (2009) Association of HLA-C and HCP5 gene regions with the clinical
course of HIV-1 infection. AIDS 23: 19–28.
17. Catano G, Kulkarni H, He W, Marconi VC, Agan BK, et al. (2008) HIV-1
disease-influencing effects associated with ZNRD1, HCP5 and HLA-C alleles
are attributable mainly to either HLA-A10 or HLA-B*57 alleles. PLoS ONE 3:
e3636.
18. Limou S, Le Clerc S, Coulonges C, Carpentier W, Dina C, et al. (2009)
Genomewide association study of an AIDS-nonprogression cohort emphasizes
the role played by HLA genes (ANRS Genomewide Association Study 02).
J Infect Dis 199: 419–426.
19. Dalmasso C, Carpentier W, Meyer L, Rouzioux C, Goujard C, et al. (2008)
Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in
HIV-1 infection: the ANRS Genome Wide Association 01 study. PLoS ONE 3:
e3907.
20. Le Clerc S, Limou S, Coulonges C, Carpentier W, Dina C, et al. (2009)
Genomewide association study of a rapid progression cohort identifies new
susceptibility alleles for AIDS (ANRS Genomewide Association Study 03).
J Infect Dis 200: 1194–1201.
21. Herbeck JT, Gottlieb GS, Winkler CA, Nelson GW, An P, et al. (2010)
Multistage genomewide association study identifies a locus at 1q41 associated
with rate of HIV-1 disease progression to clinical AIDS. J Infect Dis 201:
618–626.
22. Pelak K, Goldstein DB, Walley NM, Fellay J, Ge D, et al. (2010) Host
Determinants of HIV-1 Control in African Americans. J Infect Dis 201:
1141–1149.
23. Troyer JL, Nelson GW, Lautenberger JA, Chinn L, McIntosh C, et al. (2011)
Genome-wide Association Study Implicates PARD3B-based AIDS Restriction.
J Infect Dis 203: 1491–1502.
24. De Wolf F, Spijkerman I, Schellekens PThA, Langendam M, Kuiken CL, et al.
(1997) AIDS prognosis based on HIV-1 RNA, CD4
+ T cell count and function:
Markers with reciprocal predictive value over time after seroconversion. AIDS
11: 1799–1806.
25. Mellors JW, Kingsley L, Rinaldo CR, Jr., Todd J, Hoo BS, et al. (1995)
Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion.
Ann Intern Med 122: 573–579.
26. Rodriguez B, Sethi AK, Cheruvu VK, Mackay W, Bosch RJ, et al. (2006)
Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in
untreated HIV infection. JAMA 296: 1498–1506.
27. Mellors JW, Margolick JB, Phair JP, Rinaldo CR, Detels R, et al. (2007)
Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 Cell count slope for
progression to AIDS and death in untreated HIV-1 infection. JAMA 297:
2349–2350.
28. Spijkerman IJB, Prins M, Goudsmit J, Veugelers PJ, Coutinho RA, et al. (1997)
Early and late HIV-1 RNA level and its association with other markers and
disease progression in long-term AIDS-free homosexual men. AIDS 11:
1383–1388.
29. Steemers FJ, Gunderson KL (2007) Whole genome genotyping technologies on
the BeadArray platform. Biotechnol J 2: 41–49.
30. Centers for disease control (1993) 1993 revised classification system for HIV
infection and expanded surveillance case definition for AIDS among adolescents
and adults. MMWR 41(RR-17): 1–19.
31. Loeuillet C, Deutsch S, Ciuffi A, Robyr D, Taffe P, et al. (2008) In vitro whole-
genome analysis identifies a susceptibility locus for HIV-1. PLoS Biol 6: e32.
32. He JC, Husain M, Sunamoto M, D’Agati VD, Klotman ME, et al. (2004) Nef
stimulates proliferation of glomerular podocytes through activation of Src-
dependent Stat3 and MAPK1,2 pathways. J Clin Invest 114: 643–651.
33. Kawashima Y, Pfafferott K, Frater J, Matthews P, Payne R, et al. (2009)
Adaptation of HIV-1 to human leukocyte antigen class I. Nature 458: 641–645.
34. Schellens IM, Navis M, van Deutekom HW, Boeser-Nunnink B, Berkhout B,
et al. (2009) Adaptation of HIV-1 to the human immune system at the
population level is driven by protective HLA-B alleles. Retrovirology 6: O41.
35. De Wolf F, Lange JMA, Houweling JTM, Coutinho RA, Schellekens PThA,
et al. (1988) Numbers of CD4
+ cells and the levels of core antigens of and
antibodies to the human immunodeficiency virus as predictors of AIDS among
seropositive homosexual men. J Infect Dis 158: 615–622.
GWAS on AIDS Disease Progression
PLoS ONE | www.plosone.org 5 July 2011 | Volume 6 | Issue 7 | e2220836. Van Griensven GJP, De Vroome EMM, Goudsmit J, Coutinho RA (1989)
Changes in sexual behaviour and the fall in incidence of HIV infection among
homosexual men. Br Med J 298: 218–221.
37. Kwa D, van Rij RP, Boeser-Nunnink B, Vingerhoed J, Schuitemaker H (2003)
Association between an interleukin-4 promoter polymorphism and the
acquisition of CXCR4 using human immunodeficiency virus type 1 variants.
AIDS 17: 981–985.
38. Meyer L, Magierowska M, Hubert J-B, Theodorou I, Serococohort, et al. (1999)
CC-chemokine receptor variants, SDF-1 polymorphism, and disease progression
in 720 HIV-infected patients. AIDS 13: 624–626.
39. van Rij RP, De Roda Husman AM, Brouwer M, Goudsmit J, Coutinho RA,
et al. (1998) Role of CCR2 genotype in the clinical course of syncytium-inducing
(SI) or non-SI human immunodeficiency virus type 1 infection and in the time to
conversion to SI virus variants. J Infect Dis 178: 1806–1811.
40. van Rij RP, Broersen S, Goudsmit J, Coutinho RA, Schuitemaker H (1998) The
role of a stromal cell-derived factor-1 chemokine gene variant in the clinical
course of HIV-1 infection. AIDS 12: F85–F90.
41. van Haastrecht HJ, van Ameijden EJ, van den Hoek JA, Mientjes GH, Bax JS,
et al. (1996) Predictors of mortality in the Amsterdam cohort of human
immunodeficiency virus (HIV)-positive and HIV-negative drug users.
Am J Epidemiol 143: 380–391.
42. Geskus RB (2000) On the inclusion of prevalent cases in HIV/AIDS natural
history studies through a marker-based estimate of time since seroconversion.
Stat Med 19: 1753–1769.
43. Ge D, Zhang K, Need AC, Martin O, Fellay J, et al. (2008) WGAViewer:
software for genomic annotation of whole genome association studies. Genome
Res 18: 640–643.
44. Aulchenko YS, Struchalin MV, van Duijn CM (2010) ProbABEL package for
genome-wide association analysis of imputed data. BMC Bioinformatics 11: 134.
GWAS on AIDS Disease Progression
PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e22208